COVID-19 and thrombosis: From bench to bedside
MAM Ali, SA Spinler - Trends in cardiovascular medicine, 2021 - Elsevier
Abstract Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by
the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite …
the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite …
Anticoagulation in COVID-19: a systematic review, meta-analysis, and rapid guidance from Mayo Clinic
RD McBane II, VDT Roldan, AS Niven, RK Pruthi… - Mayo Clinic …, 2020 - Elsevier
A higher risk of thrombosis has been described as a prominent feature of coronavirus
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …
disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis …
Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review
Introduction The pandemic of COVID-19 has been caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) virus. Apart from respiratory malfunction, COVID-19 …
syndrome coronavirus 2 (SARS-CoV-2) virus. Apart from respiratory malfunction, COVID-19 …
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis
2. Methods This study followed the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) reporting guideline (Supplementary file 1). Data were obtained …
Meta-analyses (PRISMA) reporting guideline (Supplementary file 1). Data were obtained …
An insight into recent advances on platelet function in health and disease
PK Chaudhary, S Kim, S Kim - International journal of molecular sciences, 2022 - mdpi.com
Platelets play a variety of roles in vascular biology and are best recognized as primary
hemostasis and thrombosis mediators. Platelets have a large number of receptors and …
hemostasis and thrombosis mediators. Platelets have a large number of receptors and …
Cerebral venous thrombosis in COVID-19
R Ghosh, D Roy, A Mandal, SK Pal, BC Swaika… - Diabetes & Metabolic …, 2021 - Elsevier
Background and aims Initially, novel severe acute respiratory syndrome coronavirus (SARS-
CoV-2) was considered primarily a respiratory pathogen. However, with time it has behaved …
CoV-2) was considered primarily a respiratory pathogen. However, with time it has behaved …
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events
Awareness of racial/ethnic disparities represents a key challenge for healthcare systems that
attempt to provide effective healthcare and to reduce existing inequalities in the use of and …
attempt to provide effective healthcare and to reduce existing inequalities in the use of and …
Vaccine design and delivery approaches for COVID-19
K Shahzamani, F Mahmoudian… - International …, 2021 - Elsevier
COVID-19 is still a deadly disease that remains yet a major challenge for humans. In recent
times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of …
times, many large pharmaceutical and non-pharmaceutical companies have invested a lot of …
[HTML][HTML] Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus
N Mackman, SP Grover, S Antoniak - Journal of Thrombosis and …, 2021 - Elsevier
Tissue factor (TF) is induced in a variety of cell types during viral infection, which likely
contributes to disseminated intravascular coagulation and thrombosis. TF‐expressing cells …
contributes to disseminated intravascular coagulation and thrombosis. TF‐expressing cells …
[HTML][HTML] Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease
The majority of individuals infected with SARS-CoV-2 have mild-to-moderate COVID-19
disease. Convalescence from mild-to-moderate (MtoM) COVID-19 disease may be …
disease. Convalescence from mild-to-moderate (MtoM) COVID-19 disease may be …